Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, Jiangsu, China.
No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
J Transl Med. 2024 Jun 19;22(1):580. doi: 10.1186/s12967-024-05389-z.
The importance of the immune microenvironment in poorly cohesive carcinoma (PCC) has been highlighted due to its limited response rate to conventional therapy and emerging treatment resistance. A combination of clinical cohorts, bioinformatics analyses, and functional/molecular experiments revealed that high infiltration of Interferon Induced Protein with Tetratricopeptide Repeats 1 (IFIT1) + tumor-associated neutrophils (TANs) is a distinguishing feature of PCC patients. Upregulation of IFIT1 + TANs promote migration and invasion of gastric cancer (GC) cell lines (MKN45 and MKN74) and stimulates the growth of cell-derived xenograft models. Besides, by promoting macrophage secreted phosphoprotein 1 (SPP1) expression and facilitating cancer-associated fibroblast and endothelial cell recruitment and activation through TANs, IFIT1 promotes a mesenchymal phenotype, which is associated with a poor prognosis. Importantly, compared to non-PCC (NPCC), PCC tumors is more immunosuppressive. Mechanistically, IFIT1 can be stimulated by IFN-γ and contributes to the expression of Programmed Cell Death 1 Ligand (PDL1) in TANs. We demonstrated in mouse models that IFIT1 + PDL1 + TANs can induce acquired resistance to anti-PD-1 immunotherapy, which may be responsible for the difficulty of PCC patients to benefit from immunotherapy. This work highlights the role of IFIT1 + TANs in mediating the remodeling of the tumor immune microenvironment and immunotherapeutic resistance and introduces IFIT1 + TANs as a promising target for precision therapy of PCC.
免疫微环境在黏附性差的癌(PCC)中的重要性已得到凸显,因为其对常规治疗的反应率有限,且治疗耐药性不断出现。临床队列、生物信息学分析和功能/分子实验的综合结果表明,干扰素诱导蛋白具有四肽重复序列 1(IFIT1)+肿瘤相关中性粒细胞(TAN)的高浸润是 PCC 患者的一个显著特征。IFIT1+TAN 的上调可促进胃癌(GC)细胞系(MKN45 和 MKN74)的迁移和侵袭,并刺激细胞衍生的异种移植模型的生长。此外,IFIT1 通过促进巨噬细胞分泌的磷蛋白 1(SPP1)的表达,并通过 TAN 促进癌症相关成纤维细胞和内皮细胞的募集和激活,促进间充质表型,这与预后不良相关。重要的是,与非 PCC(NPCC)相比,PCC 肿瘤的免疫抑制作用更强。在机制上,IFIT1 可被 IFN-γ 刺激,并有助于 TAN 中程序性细胞死亡配体 1(PDL1)的表达。我们在小鼠模型中证明,IFIT1+PDL1+TAN 可诱导对抗 PD-1 免疫治疗的获得性耐药,这可能是 PCC 患者难以从免疫治疗中获益的原因。这项工作强调了 IFIT1+TAN 在介导肿瘤免疫微环境重塑和免疫治疗耐药中的作用,并提出 IFIT1+TAN 作为 PCC 精准治疗有前途的靶点。